Nautilus Biotechnology
Facts
- HQ
- Seattle
- Sectors
- Biotechnology Research
- Founded
- 2016
- Employees
- 150
- Stage
- Public
- Total raised
- $200M SEC Form D filings Total of this company's SEC Form D filings
- Last round
- $200M · Jun 2021 SEC Form D
- Founders
- Sujal Patel, Parag Mallick, PhD
Nautilus CEO Sujal Patel Delays Biotech Product Launch to Late 2026, Lays Off 16% Workforce Amid Strategic Shift
Nautilus Biotechnology laid off 16% of its workforce and delayed its product launch to late 2026 to pursue a higher-performance proteomics platform. CEO Sujal Patel emphasized the company’s strong financial position with over $206 million in cash despite the stock price drop.
Nautilus Biotechnology Lays Off 16% of Staff, Postpones Proteome Platform Launch to Late 2026
Nautilus Biotechnology laid off 16% of its workforce to extend its cash runway into 2027 and delayed the commercial release of its proteome analysis platform until late 2026. The company aims to control operating expenses and maximize its impact on biological science, focusing on proteomics to advance drug development.
Symbl Names Former GE Healthcare CTO Selvan Senthivel as CTO; Nautilus Biotechnology Hires Ken Suzuki as CMO
Symbl, a Seattle-based generative AI startup, appointed Selvan Senthivel, former GE HealthCare CTO, as its new CTO, while Nautilus Biotechnology named Ken Suzuki as its CMO. Additionally, William Canestaro stepped down from the Washington Research Foundation, and Milkana Brace joined the Technology Alliance board.
GeekWire Week in Review (May 14, 2023): Top stories include ex-CFO indicted over $35M crypto transfer, Bezos’ $500M yacht, and Amazon legal/personnel news
GeekWire's Week in Review for May 14, 2023 lists the site's most-read stories, including a Seattle startup ex-CFO indicted over an alleged $35M crypto transfer, Jeff Bezos' $500M yacht, and Amazon-related legal and personnel news.
Seattle’s Banzai to Go Public via SPAC with 7GC Holdings and Acquire Hyros for $110 Million
Seattle marketing software startup Banzai announced it will go public via a SPAC merger with 7GC Holdings and pay $110 million to acquire marketing optimization company Hyros after the deal closes. Founded in 2016, Banzai has pivoted to provide an end-to-end video engagement marketing platform and now employs 94 people.
Seattle Biotech Intrinsic Medicine to Go Public via SPAC Merger Raising $178.8M for Human Milk-Based Therapies
Seattle biotech startup Intrinsic Medicine, developing therapies based on human milk molecules, plans to go public via a SPAC merger with Phoenix Biotech Acquisition Corp to raise $178.8 million. The company aims to initiate a phase 2 trial for irritable bowel syndrome with top-line data expected in the first half of 2024.
Rover Rings Nasdaq Bell After SPAC IPO, Posts Profit and 130% Revenue Growth Amid Challenges
Seattle-based Rover celebrated ringing the Nasdaq opening bell on August 8 after a year as a public company via a SPAC, reporting profitability and 130% revenue growth despite past layoffs and a share decline of over 61%. CEO Aaron Easterly expressed confidence in international expansion amid rising competition and regulatory challenges.
Former Microsoft VP Gavriella Schuster Joins Nerdio Board; Ex-Mailchimp CPO Natalia Williams Hired by Hootsuite; Ex-Amazon Product Leader Sophi Kim Joins Shelf Engine
Gavriella Schuster, former Microsoft VP, joined Nerdio's board, Natalia Williams became Hootsuite's CPO, and Sophi Kim, ex-Amazon product leader, joined Shelf Engine as head of product management. These strategic hires bolster leadership at companies focused on cloud services, social media management, and grocery tech.
Andreessen Horowitz, Madrona and other tech VCs ramp up bets on AI-driven biotech startups as founders from software enter life sciences
Tech venture capital firms like Andreessen Horowitz and Seattle’s Madrona Venture Group are increasingly investing in life-science startups that use AI, machine learning and data science to speed drug discovery and development. Investors are following founders who transitioned from software to biotech—such as Sujal Patel of Nautilus and Terry Myerson of Truveta—seeing reduced perceived risk and new opportunity at this intersection.
Madrona Venture Group leads $60M Series A in Terray Therapeutics to fund AI‑powered drug discovery
Pasadena-based Terray Therapeutics raised $60 million in a Series A led by Seattle’s Madrona Venture Group to advance its nanotechnology chips and AI-driven drug discovery screening.
A-Alpha Bio raises $20M Series A led by Madrona to expand Seattle lab and scale protein-discovery platform
University of Washington spinout A-Alpha Bio raised $20 million in Series A funding led by Madrona Venture Group to expand downtown Seattle lab space and grow its machine-learning team for its protein-discovery platform. The company combines computational tools and yeast-based experiments to generate large protein-interaction datasets used to predict therapeutic protein candidates for diseases including COVID-19.
Former Tech Leaders Join Biotech: Isilon Founder Sujal Patel, Ex-Microsoft Terry Myerson and Others Lead AI-Driven Life Sciences Startups
Several former software and tech executives are moving into biotech and life sciences startups, bringing AI, machine learning, and tech-style business models to companies that analyze proteins, microbes, and medical records. Their tech backgrounds are reshaping product development and funding approaches at firms such as Nautilus Biotechnology, Truveta, insitro and Viome.
Remitly files S-1 ahead of IPO after 2020 revenue doubles to $257M and $1.5B valuation
Remitly filed an S-1 ahead of a conventional IPO, reporting $257M revenue and a $32.5M net loss for 2020 and $202M revenue with a $9.2M loss in H1 of the current year, with a $1.5B valuation from a July funding round and roughly $16.1B in trailing 12-month send volume.
Icosavax IPO: Seattle biotech raises $180M, stock jumps 200% on first trading day (ICVX)
Seattle biotech Icosavax surged more than 200% on its NASDAQ debut after raising over $180 million by pricing shares at $15; the company develops virus-like particle vaccines and recently began phase 1/2 trials for a COVID-19 vaccine supported by a $10 million Gates Foundation grant.
Modulus Therapeutics, spun out of the Allen Institute for AI, raises $3.5M to engineer enhanced NK cell therapies
Modulus Therapeutics, a Seattle cell-therapy startup spun out of the Allen Institute for AI, raised $3.5 million in seed funding to use lab research and machine learning to engineer enhanced natural killer (NK) cells for anti-tumor therapies. Founders Max Darnell and Bryce Daines aim to develop a discovery platform to generate NK cell product candidates for larger cellular therapy companies.
Seattle startups raise record $3.1B in H1 2021, producing 12 local unicorns as Auth0 exits for $6.5B
Seattle-area startups raised a record $3.1 billion across 205 deals in H1 2021, driven by mega-rounds that produced at least 12 local unicorns and broader Pacific Northwest tech funding topping $5 billion. National VC activity and IPO/M&A dollar volumes are also surpassing prior records, with major exits like Auth0’s $6.5 billion acquisition by Okta highlighting regional maturation.
Icosavax files for IPO after raising $150M and advancing nanoparticle COVID-19 and RSV vaccines
Seattle-based Icosavax, a 2017 spinout from the University of Washington’s Institute for Protein Design, has filed for an IPO after raising over $150 million and advancing nanoparticle-based COVID-19 and RSV vaccine candidates into early clinical trials with support from a $10 million Gates Foundation grant.
Remitly confidentially files draft SEC registration for IPO as it eyes roughly $5 billion valuation
Remitly, a Seattle-based mobile remittance company founded in 2011, confidentially submitted a draft registration statement with the SEC for a proposed IPO while preparing for a potential $5 billion valuation; it previously raised $85 million in July at a $1.5 billion valuation and recently received an undisclosed equity investment from Visa.
Nautilus Biotechnology (NAUT) goes public via SPAC, raises $345 million to commercialize proteome analysis
Nautilus Biotechnology, co-founded by Sujal Patel and Parag Mallick, is going public on Nasdaq as NAUT through a SPAC merger that raised $345 million to advance a new proteome analysis platform aimed at accelerating biomedical research and drug development. Institutional backers include Bezos Expeditions, Vulcan Capital and Madrona Venture Group, and the deal closes on the 25th anniversary of Patel’s arrival in Seattle.
Creative Destruction Lab to launch nine-month, equity-free Seattle accelerator with Microsoft and UW for 20–25 computational health startups this November
Creative Destruction Lab (CDL) is launching a Seattle hub this November at the University of Washington to run a nine-month, equity-free accelerator for 20–25 computational health startups in partnership with Microsoft and UW’s business, engineering, and computer science schools; UW students can shadow the program. The program is funded by founding members, enforces objective milestones with the possibility of booting nonperforming companies, and stems from UW’s Innovation Roundtable efforts led by Emer Dooley and others.
SPACs Let Founders Reach Public Markets Faster and Keep Larger Equity Stakes, Say Startup Observers
The article explains how SPACs (special purpose acquisition companies) let founders and early employees reach liquidity faster and often retain larger ownership stakes than through later-stage VC or private equity rounds. Using examples like Sana Biotechnology and Seattle entrepreneur Sujal Patel, it argues SPACs can preserve founders' equity by bypassing dilutive funding rounds.
Madison McIlwain, daughter of Madrona’s Matt McIlwain, becomes associate at Defy and pursues fashion, e-commerce investing
Madison McIlwain, daughter of Madrona Venture Group managing director Matt McIlwain, followed her father's path into venture capital and is now an associate at early-stage VC Defy, bringing interests in fashion, e-commerce and the consumer supply chain. The article profiles how growing up with dinner-table discussions about startups shaped her approach to investing and highlights Defy’s co-investments with Madrona in Seattle companies like Nautilus Biotechnology and WhyLabs.
Nautilus Biotechnology to go public via Arya Sciences Acquisition Corp III SPAC, raising $350M at $900M valuation
Nautilus Biotechnology, a Seattle proteomics startup led by Sujal Patel and Parag Mallick, will go public via a SPAC merger with Arya Sciences Acquisition Corp III, raising about $350 million and valuing the company at $900 million. The deal includes a $150 million SPAC component and a $200 million PIPE, expects to close in Q2, and the combined company will trade on Nasdaq as NAUT.
Nautilus Biotechnology hires ex-Smartsheet, Isilon and GenapSys leaders as it scales proteome platform after $76M Series B
Nautilus Biotechnology, a stealthy startup co-founded by Sujal Patel and Parag Mallick, has hired three senior executives — Chris Blessington, Anna Mowry, and Subra Sankar — to expand its team and accelerate development of a platform to quantify the human proteome after a $76 million Series B.
Amazon names Anne Toth director of Alexa Trust; Zillow adds Claire Cormier Thielke to board; Lockstep exits stealth
Amazon hired Anne Toth as director of Alexa Trust to lead privacy, security, accessibility and ethics efforts for Alexa; Zillow added Claire Cormier Thielke to its board and Lockstep, a Seattle accounting-software startup founded in 2019, emerged from stealth with a founding team drawn from Avalara, Globys, e2b Teknologies and Winshuttle.
People
-
Sujal Patel Executive, Co-founder and CEO, Executive Officer, Director
